Record #558079

DFG project G:(GEPRIS)160506553

Design and cellular delivery of a modified human deoxycytidine kinase with L-nucleoside analogue activity for use in cancer therapy

Coordinator	Dr. Theresa Schweizer
Grant period	2010 - 2015
Funding body	Deutsche Forschungsgemeinschaft
	DFG
Identifier	G:(GEPRIS)160506553

Note: Poor activation and off-target cytotoxicity often limit the efficacy of nucleoside analogue pro-drugs in the clinic. Our aim is to develop a therapeutic strategy which specifically targets tumour cells and increases the efficacy of nucleoside analogue pro-drugs in the treatment of certain cancers. We will modify the enzyme human deoxycytidine kinase (dCK) to enable it to exclusively phosphorylate and activate non-physiological L-nucleosides. The modified dCK will be targeted and delivered to tumour cells by the use of single chain antibodies (scFv) or affibodies. We propose that the confined delivery of our modified dCK to tumour cells and the use of L-nucleoside analogues will provide both increased cytotoxicity and increased specificity in nucleoside analogue chemotherapy.

Recent Publications

There are no publications

Record created 2023-02-03, last modified 2024-09-27

Similar records

Rate this document:

(Not yet reviewed)

Add to personal basket
Export as Author List with IDs BibTeX (UTF-8), EndNote XML, EndNote Text, RIS, MARC, Print MARC, MARCXML, DC,
Request correction
Submit fulltext

guest :: login PUBDB
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help